Chimeric antigen receptor (CAR) T cells engineered to recognise the CD19 protein are an effective cure for B cell malignancies such as diffused large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, and B cell acute lymphoblastic leukaemia (B-ALL)1–6. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.